Biotech entity
Every one of those 1 sits in a single category, gene-therapy. ClearPoint Advanced Laboratories (CAL) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. IRRA flow Portfolio appears in 1 tracked Biotech story from August 4, 2026.
Last mentioned: Aug 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, gene-therapy. ClearPoint Advanced Laboratories (CAL) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. IRRA flow Portfolio appears in 1 tracked Biotech story from August 4, 2026. The tracked stories average 3 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 12 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering IRRA flow Portfolio. Shared-story counts are live from our verified record — not editorial picks.
Commercial Drug Delivery Readiness Target
ClearPoint aims to have its commercial infrastructure and installed base ready to support partner drug launches.
Q2 2026 Earnings Release
ClearPoint Neuro announces quarterly results and highlights FDA guidance reversal and commercial restructuring.
CAL Facility Possession
ClearPoint takes possession of the ClearPoint Advanced Laboratories, enabling new in-house services revenue from Q3 onward.
Second Quarter 2026 Ends
ClearPoint Neuro's fiscal Q2 concludes with $10.9M in revenue, 18% overall growth, but a 15% decline in Biologics and Drug Delivery.
Potential Partner BLA Submissions
Following FDA's rare disease guidance reversal, biopharma partners may file Biologics License Applications later this year.
ClearPoint Neuro's Q2 biologics revenue fell 15% as clinical trial product shipments slowed, but the newly operational CAL facility and an FDA regulatory pivot on rare diseases are expected to re-ignite growth in the cell and gene therapy delivery segment.
Source: theusnews.com · albuquerqueexpress.com
IRRA flow Portfolio is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
